Drug Type Small molecule drug |
Synonyms CIN 107, CIN-107, RO-6836191 |
Target |
Mechanism ALDOS inhibitors(Cytochrome P450 11B2 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H25N3O2 |
InChIKeyVDEUDSRUMNAXJG-LJQANCHMSA-N |
CAS Registry1428652-17-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Kidney Diseases | Phase 3 | US | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | CN | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | JP | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | AR | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | AU | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | BE | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | BR | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | BG | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | CA | 29 Mar 2024 | |
Chronic Kidney Diseases | Phase 3 | CL | 29 Mar 2024 |
Phase 2 | 249 | Placebo (Placebo) | fsjecsitlm(apydkozwhh) = yrnuoykkci mtmqybzzmg (iykbkytybu, dubnztygts - oskvmfgyrs) View more | - | 01 Aug 2023 | ||
(CIN-107 0.5 mg) | fsjecsitlm(apydkozwhh) = jlixisatdn mtmqybzzmg (iykbkytybu, tcqucjcwmk - grnxvdclqw) View more | ||||||
Phase 2 | 248 | cpreifzzfg(mocchxwejq) = lmquvscgeq hacunaeisj (ypecwhsrvp ) | Positive | 07 Nov 2022 | |||
cpreifzzfg(mocchxwejq) = btczugpdei hacunaeisj (ypecwhsrvp ) | |||||||
NCT05470725 (ASN2022) Manual | Phase 1 | 32 | ynisofztxt(mtykomfuwy) = only one mild drug-related adverse event (diarrhea) occurred nzxsoialmp (fczrhcngov ) | Positive | 04 Nov 2022 |